Jason Xu
Lawyers
Filters
MIXUE HK$3.45 billion IPO
We advised MIXUE on its IPO and HKEX listing
iQIYI $350 million convertible notes offering and concurrent private repurchases
We advised iQIYI on the transactions
Ascentage Pharma $126.4 million IPO
The IPO is the first life sciences U.S. IPO of 2025 and the first life sciences company listed on the HKEX to complete a U.S. listing
BrainAurora Medical Technology HK$583 million IPO
We advised BrainAurora on its IPO and HKEX listing
Laekna HK$236 million placement of shares
We advised Laekna on the placement of new shares
Horizon Robotics HK$5.41 billion IPO
We advised Horizon Robotics on its IPO and HKEX listing
Baicha Baidao HK$2.6 billion IPO
We advised Baicha Baidao on its IPO and HKEX listing
LianLian DigiTech HK$657 million IPO
We advised Lianlian DigiTech on its IPO and HKEX listing
Keep HK$313 million IPO
The shares are listed on the HKEX
Laekna HK$791 million IPO
We advised Laekna on its IPO and HKEX listing